The FDA has issued a complete response letter (CRL) for Johnson and Johnson’s proposed rheumatoid arthritis (RA) drug, sirukumab. Janssen Biotech, a division of Johnson and Johnson, had filed a Biologics License Application (BLA) for the interleukin-6 (IL-6) inhibitor, including data from a global phase 3 clinical development program, in September 2016.
The FDA has issued a complete response letter (CRL) for Johnson and Johnson’s proposed rheumatoid arthritis (RA) drug, sirukumab. Janssen Biotech, a division of Johnson and Johnson, had filed a Biologics License Application (BLA) for the interleukin-6 (IL-6) inhibitor, including data from a global phase 3 clinical development program, in September 2016.
“We are disappointed by this development as we feel the data accumulated to date support the efficacy and safety of sirukumab in the treatment of moderately to severely active rheumatoid arthritis,” said Newman Yeilding, MD, head of immunology development for Janssen. “We believe sirukumab represents an important therapeutic option for patients living with rheumatoid arthritis, especially for those individuals who cycle through multiple treatments and continue to struggle to find an effective option for a potentially disabling disease.”
The CRL for sirukumab does not come as a surprise to the rheumatology world; the FDA’s rejection of the drug follows an August 2, 2017, Arthritis Advisory Committee (AAC) meeting in which the voting committee members did not recommend drug approval. The AAC expressed concerns about 35 patient deaths reported during a phase 3 clinical program in patients with RA, 34 of which occurred in the sirukumab arm of the study. The most common causes of death included major cardiac adverse events (AEs), infection, and malignancy.
Sirukumab was also associated with laboratory abnormalities (decreased neutrophil count; increased liver function test values; and increased lipid parameters, including low-density lipoprotein, high-density lipoprotein, and triglycerides). These abnormalities were documented with both the 50-mg and 100-mg doses of sirukumab that were studied.
Janssen has been among several companies seeking to retain a hold on the increasingly crowded RA marketplace in the face of increasing biosimilar competition for an established biologic as its innovator infliximab (Remicade). By developing an IL-6 inhibitor for use in patients who had not had an adequate response to such products as Remicade, Janssen had likely hoped to buffer itself against further erosions of its sales from infliximab biosimilars Inflectra and Renflexis. With sirukumab’s rejection by the FDA, Janssen lags behind such approved IL-6 drugs as sarilumab (manufactured by Sanofi) and tocilizumab (Acterma) manufactured by Roche).
Janssen said that it would review the details of the CRL and create a plan for follow-up discussions of the drug’s rejection with the FDA. The company hopes to, as Yeilding said, “Gain a full understanding of FDA requirements for US approval.”
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.